title: (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
abstract: OBJECTIVE
  The objective of this study is to evaluate the therapeutic response to a novel monoclonal antibody targeting human extracellular matrix metalloproteinase inducer (EMMPRIN) in combination with gemcitabine in a pancreatic-tumor xenograft murine model by sequential 2-deoxy-2-[18F]fluoro-D-glucose ((18)F-FDG) positron emission tomography/computed tomgraphy (PET/CT) imaging.
  
  
  METHODS
  Four groups of SCID mice bearing orthotopic pancreatic tumor xenografts were injected with phosphate-buffered saline, gemcitabine (120 mg/kg BW), anti-EMMPRIN antibody (0.2 mg), or combination, respectively, twice weekly for 2 weeks, while (18)F-FDG PET/CT imaging was performed weekly for 3 weeks. Changes in mean standardized uptake value (SUV(mean)) of (18)F-FDG and volume of tumors were determined.
  
  
  RESULTS
  The tumor SUV(mean) change in the group receiving combination therapy was significantly lower than those of the other groups. Tumor-volume changes of groups treated with anti-EMMPRIN monotherapy or combined therapy were significantly lower than that of the control group.
  
  
  CONCLUSIONS
  These data provide support for clinical studies of anti-EMMPRIN therapy with gemcitabine for pancreatic cancer treatment.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
authors.forename: Nemil
authors.initials: N
authors.lastname: Shah
authors.forename: Guihua
authors.initials: G
authors.lastname: Zhai
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Knowles
authors.forename: Cecil R
authors.initials: CR
authors.lastname: Stockard
authors.forename: William E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: Naomi
authors.initials: N
authors.lastname: Fineberg
authors.forename: Tong
authors.initials: T
authors.lastname: Zhou
authors.forename: Kurt R
authors.initials: KR
authors.lastname: Zinn
authors.forename: Eben L
authors.initials: EL
authors.lastname: Rosenthal
authors.forename: Hyunki
authors.initials: H
authors.lastname: Kim
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D051926:Basigin / Q000276:immunology*; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D003287:Contrast Media; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D016513:Mice, SCID; D064847:Multimodal Imaging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000912:Antibodies, Neoplasm; D003287:Contrast Media; D003841:Deoxycytidine; D019788:Fluorodeoxyglucose F18; D051926:Basigin; D000255:Adenosine Triphosphate; D000093542:Gemcitabine